Seminars in Oncology
Volume 33 , Pages 18-25 , April 2006

Future Directions in the Treatment of Hormone-Sensitive Advanced Breast Cancer: The RAD001 (Everolimus)-Letrozole Clinical Program

  • Heidi A. Lane

      Affiliations

    • Novartis Institutes For BioMedical Research, Oncology Basel, Novartis Pharma AG, Switzerland.
    • Dr Lane is an employee of Novartis Pharma AG, Basel, Switzerland.
    • ,
  • David Lebwohl

      Affiliations

    • Novartis Oncology, East Hanover, NJ.
    • Dr Lebwohl is an employee of Novartis Pharmaceuticals, East Hanover, NJ, USA.
    • Corresponding Author InformationAddress correspondence and reprint requests to: David Lebwohl, MD, Phase II/III Oncology, Novartis Oncology, One Health Plaza, East Hanover, NJ 07936, USA

References 

  1. Bhatnagar AS , Batzl C , Hausler A . Pharmacology of non-steroidal aromatase inhibitors . In:  Pasqualini JR ,  Katzenellenbogen BS editor. Hormone-Dependent Cancer . New York, NY: Marcel Dekker; 1996;p. 155–168
  2. Miller WR . Aromatase inhibitors and breast cancer . Minerva Endocrinol . 2006;31:27–46
  3. Gradishar W . Landmark trials in endocrine adjuvant therapy for breast carcinoma . Cancer . 2006;106:975–981
  4. Veronesi U , Boyle P , Goldhirsch A , et al.   Breast cancer . Lancet . 2005;365:1727–1741
  5. Goss PE . Breast cancer prevention–Clinical trials strategies involving aromatase inhibitors . J Steroid Biochem Mol Biol . 2003;86:487–493
  6. Cuzick J , Powles T , Veronesi U , et al.   Overview of the main outcomes in breast-cancer prevention trials . Lancet . 2003;361:296–300
  7. Early Breast Cancer Trialists’ Collaborative Group . Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence (An overview of the randomized trials) . Lancet . 2005;365:1687–1717
  8. Santen RJ , Song RX , Zhang Z , et al.   Adaptive hypersensitivity to estrogen (Mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment) . J Steroid Biochem Mol Biol . 2005;95:155–165
  9. Slamon DJ , Leyland-Jones B , Shak S , Fuchs H , et al.   Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 . N Engl J Med . 2001;344:783–792
  10. Willems A , Gauger K , Henrichs C , et al.   Antibody therapy for breast cancer . Anticancer Res . 2005;24:1483–1489
  11. Marty M , Cognetti F , Maraninchi D , et al.   Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment (the M77001 study group) . J Clin Oncol . 2005;23:4265–4274
  12. Buzdar AU , Ibrahim NK , Francis D , et al.   Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy (Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer) . J Clin Oncol . 2005;23:3676–3685
  13. Piccart-Gebhart MJ , Procter M , Leyland-Jones B , et al.   Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer . N Engl J Med . 2005;353:1659–1672
  14. Romond EH , Perez EA , Bryant J , et al.   Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer . N Engl J Med . 2005;353:1673–1684
  15. Rose C , Vtoraya O , Pluzanska A , et al.   An open randomised trial of second-line endocrine therapy in advanced breast cancer. Comparison of the aromatase inhibitors letrozole and anastrozole . Eur J Cancer . 2003;39:2318–2327
  16. Goss PE , Ingle JN , Martino S , et al.   A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer . N Engl J Med . 2003;349:1793–1802
  17. Thürlimann B , Keshaviah A , Coates AS , et al.  Breast International Group (BIG) 1-98 Collaborative Group   A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer . N Engl J Med . 2005;353:2747–2757
  18. Eiermann W , Paepke S , Appfelstaedt J , et al.  Letrozole Neo-Adjuvant Breast Cancer Study Group   Preoperative treatment of postmenopausal breast cancer patients with letrozole (A randomized double-blind multicenter study) . Ann Oncol . 2001;12:1527–1532
  19. Bjornsti MA , Houghton PJ . The TOR pathway (a target for cancer therapy) . Nat Rev Cancer . 2004;4:335–348
  20. Mita MM , Mita A , Rowinsky EK . Mammalian target of rapamycin (A new molecular target for breast cancer) . Clin Breast Cancer . 2003;4:126–137
  21. Gangloff YG , Mueller M , Dann SG , et al.   Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development . Mol Cell Biol . 2004;24:9508–9516
  22. Vivanco I , Sawyers CL . The phosphatidylinositol 3-Kinase AKT pathway in human cancer . Nat Rev Cancer . 2002;2:489–501
  23. Johnston SR . Combinations of endocrine and biological agents (present status of therapeutic and presurgical investigations) . Clin Cancer Res . 2005;11:889S–899S
  24. Schiff R , Massarweh SA , Shou J , et al.   Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance . Clin Cancer Res . 2004;10:331S–336S
  25. Lane HA , Boulay B , Hattenberger M , et al.   The orally active rapamycin derivative RAD001 has potential as an antitumor agent with a broad antiproliferative activity (PTEN as a molecular determinant of response) . Proc Am Assoc Cancer Res . 2003;44:314; (abstr 1608)
  26. Beuvink I , Boulay A , Fumagalli S , et al.   The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation . Cell . 2005;120:747–759
  27. O’Reilly T , Vaxelaire J , Muller M , et al.   In vivo activity of RASD001, an orally active rapamycin derivative, in experimental tumor models . Proc Am Assoc Cancer Res . 2002;43:71; (abstr 359)
  28. Boulay A , Zumstein-Mecker S , Stephan C , et al.   Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells . Cancer Res . 2004;64:252–261
  29. Majumder PK , Febbo PG , Bikoff R , et al.   mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways . Nat Med . 2004;10:594–601
  30. Goudar RK , Shi Q , Hjelmeland MD , et al.   Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition . Mol Cancer Ther . 2005;4:101–112
  31. Beuvink I , O’Reilly T , Zumstein S , et al.   Antitumor activity of RAD001, an orally active rapamycin derivative . Proc Am Assoc Cancer Res . 2001;42:366; (abstr 1972)
  32. O’Reilly TM , Wood JM , Amanda L-E , et al.   Differential anti-vascular effects of mTOR or VEGFR pathway inhibition (A rational basis for combining RAD001 and PTK787/ZK222584) . Proc Am Assoc Cancer Res . 2005;46:715; (abstr 3038)
  33. Boulay A , Stephan C , Zumstein-Mecker S , et al.   Phospho-AKT levels as a potential biomarker of in vitro sensitivity of tumor cell lines to the mTOR pathway inhibitor RAD001 . (abstr B170) Clin Cancer Res . 2003;9(suppl):159
  34. O’Reilly T , Muller M , Hattenberger M , et al.   Antitumor activity of RAD001 in combination with cytotoxic agents . Proc Am Assoc Cancer Res . 2003;44:136; (abstr 713)
  35. Stephan C , Zumstein-Mecker S , Gerboth S , et al.   A potential for combining the rapamycin derivative RAD001 (everolimus) with the EGF/ErbB2/VEGF receptor tyrosine kinase inhibitor AEE788 in human cancer . Eur J Cancer . 2004;2:16; (abstr 40)
  36. Dengler J , von Bubnoff N , Decker T , et al.   Combination of imatinib with rapamycin or RAD001 acts synergistically only in Bcr-Abl-positive cells with moderate resistance to imatinib . Leukemia . 2005;19:1835–1838
  37. O’Reilly KE , Rojo F , She QB , et al.   mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt . Cancer Res . 2006;66:1500–1508
  38. Fresno Vara JA , Casado E , de Castro J , et al.   PI3K/Akt signalling pathway and cancer . Cancer Treat Rev . 2004;30:193–204
  39. deGraffenried LA , Friedrichs WE , Russell DH , et al.   Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity . Clin Cancer Res . 2004;10:8059–8067
  40. Perez-Tenorio G , Stal O  Southeast Sweden Breast Cancer Group . Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients . Br J Cancer . 2002;86:540–545
  41. Campbell RA , Bhat-Nakshatri P , Patel NM , et al.   Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha (A new model for anti-estrogen resistance) . J Biol Chem . 2001;276:9817–9824
  42. Yue W , Wang JP , Conaway MR , et al.   Adaptive hypersensitivity following long-term estrogen deprivation (involvement of multiple signal pathways) . J Steroid Biochem Mol Biol . 2003;86:265–274
  43. Ellis M . Overcoming endocrine therapy resistance by signal transduction inhibition . Oncologist . 2004;9(suppl 3):20–26
  44. Kurokawa H , Lenferink AE , Simpson JF , et al.   Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells . Cancer Res . 2000;60:5887–5894
  45. Kurokawa H , Arteaga CL . ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms . Clin Cancer Res . 2003;9:511S–515S
  46. Tabernero J . A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with advanced solid tumors . Proc Am Soc Clin Oncol . 2005;23:193; (abstr 3007)
  47. O’Donnell A , Faivre S , Judson I , et al.   A phase I study of the oral mTOR inhibitor RAD001 as monotherapy to identify the optimal biologically effective dose using toxicity, pharmacokinetic (PK) and pharmacodynamic (PD) endpoints in patients with solid tumors . Proc Am Soc Clin Oncol . 2003;22:200; (abstr 803)
  48. Lane H , Tanaka C , Kovarik J , et al.   Preclinical and clinical pharmacokinetic/pharmacodynamic (PK/PD) modeling to help define an optimal biological dose for the oral mTOR inhibitor, RAD001, in oncology . (abstr 951) Proc Am Soc Clin Oncol . 2003;22:237
  49. Smith IE . Aromatase inhibitors-extending the benefits of adjuvant therapy beyond tamoxifen . Breast . 2004;13(suppl):3–9
  50. Janicke F . Are all aromatase inhibitors the same? A review of the current evidence . Breast . 2004;13(suppl 1):10–18
  51. Geisler J , Haynes B , Anker G , et al.   Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study . J Clin Oncol . 2002;20:751–757
  52. Boulay A , Rudloff J , Ye J , et al.   Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer . Clin Cancer Res . 2005;11:5319–5328
  53. Pang H , Faber LE . Estrogen and rapamycin effects on cell cycle progression in T47D breast cancer cells . Breast Cancer Res Treat . 2001;70:21–26
  54. Castoria G , Migliaccio A , Bilancio A , et al.   PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells . EMBO J . 2001;20:6050–6059
  55. Awada A , Cardoso F , Fontaine C , et al.   A phase Ib study of the mTOR inhibitor RAD001 (everolimus) in combination with letrozole (Femara), investigating safety and pharmacokinetics in patients with advanced breast cancer stable or slowly progressing on letrozole . Breast Cancer Res Treat . 2004;88(suppl 1):S234; (abstr 6043)
  56. Lerut E , Roskams T , Goossens E , et al.   Molecular pharmacodynamic (MPD) evaluation of dose and schedule of RAD001 (everolimus) in patients with operable prostate carcinoma (PC) . (abstr 3071) Proc Am Soc Clin Oncol . 2005;23:209
  57. Pacey S , Rea D , Steven N , et al.   Results of a phase 1 clinical trial investigating a combination of the oral mTOR-inhibitor Everolimus (E, RAD001) and Gemcitabine (GEM) in patients (pts) with advanced cancers . Proc Am Soc Clin Oncol . 2004;23:224; (abstr 3120)
  58. Campone M , Levy V , Delecroix V , et al.   Phase Ib and pharmacokinetic studies of Everolimus (RAD001), a novel oral mTOR-inhibitor, with paclitaxel in patients with advanced solid tumors . Eur J Cancer . 2004;2:108; (abstr)
  59. van Oosterom A , Reichart P , Blay J , et al.   A phase I/II trial of the oral mTOR-inhibitor everolimus (E) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM (Study update) . Proc Am Soc Clin Oncol . 2005;23:824; (abstr 9033)
  60. Milton DT . Phase I/II trial of gefitinib and RAD001 (everolimus) in patients (pts) with advanced non–small cell lung cancer (NSCLC) . Proc Am Soc Clin Oncol . 2005;23:646; (abstr 7104)

PII: S0093-7754(06)00172-2

doi: 10.1053/j.seminoncol.2006.03.024

Seminars in Oncology
Volume 33 , Pages 18-25 , April 2006

Article Tools

* Image Usage & Resolution